Introduction
============

The most recently reported estimate of the annual global incidence of endometrial carcinoma (EC) is 320,000 new cases ([@b1-mco-0-0-1551]), making it the most common gynecological malignancy ([@b2-mco-0-0-1551]), with an estimated annual global mortality of 76,000 ([@b1-mco-0-0-1551]). The surgical management and prediction of outcome for patients with EC are guided by the International Federation of Gynecology and Obstetrics (FIGO) staging system ([@b3-mco-0-0-1551]). However, patients with the same disease stage may experience very different clinical courses ([@b1-mco-0-0-1551],[@b4-mco-0-0-1551]). To elucidate the reasons for these differences, several investigators have evaluated the effect of various tumor attributes on outcomes to delineate prognostic factors, such as histological subtype and FIGO stage ([@b4-mco-0-0-1551]--[@b6-mco-0-0-1551]). Unfortunately, preoperative evaluations generally require invasive, costly and time-consuming procedures, such as fractional curettage, transvaginal ultrasonography, magnetic resonance imaging, or hysteroscopic assessment ([@b1-mco-0-0-1551],[@b7-mco-0-0-1551]--[@b9-mco-0-0-1551]). Early detection and improvements in surgical techniques and chemotherapy have contributed to improvements in prognosis. However, precise predictions of prognosis remain elusive, although they are crucial for optimal treatment decisions.

Previous studies of various cancer types have reported that cancers associated with a systemic inflammatory response are associated with poorer prognosis ([@b10-mco-0-0-1551]--[@b12-mco-0-0-1551]). In particular, the Glasgow prognostic score (GPS) is useful for predicting prognosis in a number of cancer types ([@b13-mco-0-0-1551]--[@b16-mco-0-0-1551]). The GPS is derived from an inflammation-based prognostic scoring system, including serum C-reactive protein (CRP) and albumin levels. A high pretreatment GPS has been reported to be a poor prognostic factor for patients with cervical and ovarian carcinomas ([@b17-mco-0-0-1551]--[@b20-mco-0-0-1551]), but it has not been evaluated thoroughly in EC. Although the prognosis of EC is generally favorable ([@b21-mco-0-0-1551]), it is poor for a proportion of the patients. Therefore, the aim of the present study was to elucidate the clinical impact of a high pretreatment GPS in patients with EC.

Patients and methods
====================

### Patients

The present study was approved by the Ethics Committee of Shimane Medical University. A total of 118 patients with EC who underwent surgery at the University Hospital of Shimane (Izumo, Japan) between January 1997 and December 2013 were investigated. Patients with insufficient data, non-surgical treatment, secondary malignancies and hematological diseases were excluded.

Diagnosis was based on conventional morphological examinations of hematoxylin and eosin-stained sections, and tumors were classified according to the World Health Organization classification ([@b22-mco-0-0-1551]). Tumor staging and grading were performed according to the FIGO classification. All patients underwent surgery (total abdominal hysterectomy and bilateral salpingo-oophorectomy), and those with a cancer stage \>1a and grade 1 underwent pelvic lymph node dissection and adjuvant platinum and taxane chemotherapy. Pelvic lymph node dissection and adjuvant chemotherapy were omitted in EC patients with stage 1a and grade 1 disease.

### Measurement of GPS

Pretreatment serum CRP and albumin levels were measured 4 weeks prior to surgery. The pretreatment GPS was classified as follows: Patients with both a high CRP level (\>1.0 mg/dl) and hypoalbuminemia (\<3.5 g/dl) were assigned a score of 2, those with only one of these biochemical abnormalities were assigned a score of 1, and those with neither of these abnormalities were assigned a score of 0 ([@b23-mco-0-0-1551]).

### Statistical analysis

Statistical analyses were conducted with SPSS software for Windows, version 19.0 (SPSS Inc., Chicago, IL, USA). Binomial logistic regression analysis was used for univariate analysis in case of ordered categorical variables. The following clinical factors were used for modeling: Patient age at diagnosis (\<60 vs. ≥60 years), stage (I/II vs. III/IV), histological type (endometrioid vs. others), tumor grade (1 vs. 2/3), pretreatment GPS (0 vs. 1 vs. 2), carbohydrate antigen (CA) 19-9 level (\<37 vs. ≥37 U/ml), and carcinoembryonic antigen (CEA) level (\<5 vs. ≥5 ng/ml). Progression-free survival (PFS) and overall survival (OS) were the endpoints of the analysis. PFS was defined as the date from initial diagnosis to initial recurrence of disease. Patients with no recurrence at their last follow-up visit were censored at that time. OS was defined as the date from initial diagnosis to death. Patients alive at their last follow-up visit were censored at that time. Kaplan-Meier curves and log-rank tests were used to plot the survival data and determine the statistical significance of survival differences. Variables that were significant (P\<0.05) in the univariate analysis were entered into the multivariate analysis. The Cox\'s proportional hazards model was used for the prognostic analysis. Data of patients who were lost to follow-up were censored. All reported P-values were two-sided, and P\<0.05 was considered to indicate statistically significant differences.

Results
=======

### Patient and clinical characteristics

A total of 118 patients with EC were enrolled. Their clinicopathological characteristics are summarized in [Table I](#tI-mco-0-0-1551){ref-type="table"}.

### Associations between clinicopathological parameters and preoperative GPS in patients with EC

Binomial logistic regression analyses ([Table II](#tII-mco-0-0-1551){ref-type="table"}) were used to evaluate the associations between patient clinicopathological factors and pretreatment GPS. Clinical stage (P\<0.001), histological type (P=0.007) and tumor grade (P=0.006) were found to be significantly associated with pretreatment GPS.

### Univariate and multivariate analyses of prognostic factors in patients with EC

Age, clinical stage, histological type, grade, pretreatment GPS, CA19-9, and CEA levels were investigated in univariate analyses of survival. As regards PFS, age (P=0.024), stage (P\<0.001), histological type (P\<0.001), grade (P=0.004) and pretreatment GPS (P\<0.001; [Fig. 1A](#f1-mco-0-0-1551){ref-type="fig"}) were found to be significant predictors. Multivariate analysis revealed that advanced stage (III/IV) \[hazard ratio (HR)=3.981; 95% confidence interval (CI): 1.712--9.256; P=0.001\], histological type (except for endometrioid; HR=2.794; 95% CI: 1.249--6.248; P=0.012), and high pretreatment GPS (HR=1.792; 95% CI: 1.076--2.985; P=0.025) were independent negative predictors for PFS ([Table III](#tIII-mco-0-0-1551){ref-type="table"}). As regards OS, as shown in [Table IV](#tIV-mco-0-0-1551){ref-type="table"}, stage (P\<0.001), histological type (P\<0.001), grade (P=0.039), pretreatment GPS (P\<0.001; [Fig. 1B](#f1-mco-0-0-1551){ref-type="fig"}) and CEA level (P=0.013) were found to be significant predictors. The multivariate analysis revealed that advanced stage (stage III/IV) (HR=5.469; 95% CI: 1.649--18.137; P=0.005), histological type (except for endometrioid; HR=4.214; 95% CI: 1.346--13.197; P=0.014), high pretreatment GPS (HR=2.126; 95% CI: 1.021--4.428; P=0.044) and CEA level (≥5.0 ng/ml; HR=4.110; 95% CI: 1.246--13.553; P=0.020) were significant independent negative predictors for OS ([Table IV](#tIV-mco-0-0-1551){ref-type="table"}).

Discussion
==========

To the best of our knowledge, this is the first report to demonstrate that a high preoperative GPS is a negative prognostic factor in patients with EC. Using Cox\'s regression analysis, it was revealed that a high pretreatment GPS is an independent prognosticator in EC, which is consistent with its prognostic ability in other malignancies.

The mechanisms of the correlation between an elevated GPS and poor prognosis remain unclear. As GPS is determined by CRP and albumin levels, proposed explanations include the following: i) Circulating CRP levels may indicate inflammatory status in the tumor microenvironment ([@b23-mco-0-0-1551]). Tumor growth, invasion and metastasis may be stimulated by inflammation in the tumor microenvironment ([@b20-mco-0-0-1551],[@b24-mco-0-0-1551]). ii) CRP production is stimulated by proinflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor (TNF)-α, which may promote tumor cell survival, growth and migration ([@b25-mco-0-0-1551]--[@b27-mco-0-0-1551]); elevated CRP levels may reflect increased levels of these cytokines. iii) CRP may protect tumor cells from apoptosis. Human CRP binds Fc gamma receptors, and by activating the phosphatidylinositol 3-kinase/Akt, nuclear factor-κB and extracellular signal-regulated kinase pathways, prevents chemotherapy-induced apoptosis of myeloma cells ([@b28-mco-0-0-1551]). CRP also increases the secretion of IL-6 and exerts a synergistic effect to protect myeloma cells from chemotherapy-induced apoptosis ([@b25-mco-0-0-1551]); if these effects occur in EC, CRP may become a treatment target. iv) In addition, serum albumin levels may be decreased by proinflammatory cytokines, such as IL-6 and TNF, via inhibition of albumin production in hepatic cells ([@b10-mco-0-0-1551],[@b26-mco-0-0-1551]); thus, the possible mechanisms underlying the association between serum albumin concentration and survival are similar to those for CRP. Furthermore, since albumin is a marker of nutritional status, pretreatment hypoalbuminemia may indicate pre-existing malnutrition or poor health status ([@b29-mco-0-0-1551]).

There were certain limitations to the present study, such as its retrospective design. In addition, the GPS was measured only once, as part of a routine examination prior to treatment. The GPS has been shown to be a clinical biomarker that potentially reflects aggressive tumor biology. Therefore, longitudinal studies with continuous GPS determinations over different treatment periods are required to elucidate the association between GPS and prognosis, and the mechanisms underlying this association.

In conclusion, a high pretreatment GPS was found to be correlated with poor surgical outcomes in patients with EC. The pretreatment GPS may represent a cost-effective and convenient predictive marker for the identification of high-risk populations, which may guide clinical decision-making and improve patient outcomes.
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###### 

Kaplan-Meier estimates of the prognostic value of a high pretreatment Glasgow prognostic score (GPS) for (A) progression-free survival and (B) overall survival in patients with endometrial carcinoma.
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###### 

Clinical characteristics of the patient population (n=118).

  Characteristics           No. of patients (%)
  ------------------------- ---------------------
  Age at diagnosis, years   
    \<60                    55 (47)
    ≥60                     63 (53)
  FIGO stage                
    I, II                   79 (67)
    III, IV                 39 (33)
  Histology                 
    Endometrioid            99 (84)
    Other                   19 (16)
  Grade                     
    G1                      53 (45)
    G2, G3                  65 (55)
  Pretreatment GPS          
    0                       91 (77)
    1                       19 (16)
    2                       8 (7)
  CA19-9, U/ml              
    \<37                    93 (79)
    ≥37                     25 (21)
  CEA, ng/ml                
    \<5.0                   97 (82)
    ≥5.0                    21 (18)

CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; FIGO, International Federation of Gynecology and Obstetrics; GPS, Glasgow prognostic score.

###### 

Association of clinicopathological parameters with pretreatment Glasgow prognostic score.

                                 Pretreatment GPS             
  ------------------------- ---- ------------------ ----- --- ---------
  Age at diagnosis, years                                     0.348
    \<60                    55   45                   6   4   
    ≥60                     63   46                 13    4   
  FIGO stage                                                  \<0.001
    I, II                   79   70                   8   1   
    III, IV                 39   21                 11    7   
  Histology                                                   0.007
    Endometrioid            99   82                 12    5   
    Other                   19     9                  7   3   
  Grade                                                       0.006
    G1                      53   47                   6   0   
    G2, G3                  65   44                 13    8   
  CA19-9, U/ml                                                0.116
    \<37                    93   76                 13    4   
    ≥37                     25   16                   5   4   
  CEA, ng/ml                                                  0.567
    \<5.0                   97   79                 11    7   
    ≥5.0                    21   15                   4   1   

CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; FIGO, International Federation of Gynecology and Obstetrics; GPS, Glasgow prognostic score.

###### 

Univariate and multivariate analyses of prognostic factors for progression-free survival.

                            Univariate analysis   Multivariate analysis                                    
  ------------------------- --------------------- ----------------------- --------- ------- -------------- -------
  Age at diagnosis, years   2.559                 1.132--5.784            0.024     2.090   0.899--4.862   0.087
  FIGO stage                5.271                 2.376--11.694           \<0.001   3.981   1.712--9.256   0.001
  Histology                 4.787                 2.268--10.162           \<0.001   2.794   1.249--6.248   0.012
  Grade                     4.778                 1.662--13.738           0.004     N/A     N/A            N/A
  Pretreatment GPS          2.618                 1.654--4.154            \<0.001   1.792   1.076--2.985   0.025
  CA19-9, U/ml              0.943                 0.381--2.332            0.899     --      --             --
  CEA, ng/ml                1.978                 0.727--5.380            0.181     --      --             --

CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; GPS, Glasgow prognostic score; N/A, not available.

###### 

Univariate and multivariate analyses of prognostic factors for overall survival.

                            Univariate analysis   Multivariate analysis                                     
  ------------------------- --------------------- ----------------------- --------- ------- --------------- -------
  Age at diagnosis, years   1.976                 0.740--5.275            0.174     --      --              --
  FIGO stage                8.658                 2.802--26.754           \<0.001   5.469   1.649--18.137   0.005
  Histology                 5.447                 2.129--13.940           \<0.001   4.214   1.346--13.197   0.014
  Grade                     3.698                 1.070--12.782           0.039     N/A     N/A             N/A
  Pretreatment GPS          2.583                 1.454--4.588            \<0.001   2.126   1.021--4.428    0.044
  CA19-9, U/ml              1.392                 0.493--3.927            0.532     --      --              --
  CEA, ng/ml                4.030                 1.342--12.101           0.013     4.110   1.246--13.553   0.020

CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; GPS, Glasgow prognostic score; N/A, not available.
